MyCellHub

What MyCellHub does

MyCellHub is a Belgium-based (Leuven) software provider that develops a cloud-based Manufacturing Execution System (MES) for regulated life sciences and advanced therapy manufacturers. Founded in 2019, the company targets manufacturers of cell therapies, gene therapies, and other advanced biotherapy products who require GMP-compliant production environments and electronic records compliance under 21 CFR Part 11. Its platform replaces paper-based batch records and quality management workflows with digital equivalents, addressing the traceability, data integrity, and real-time visibility requirements specific to advanced therapy manufacturing — a vertical where most manufacturers still rely on manual documentation despite stringent regulatory expectations.

The product, branded the MyCellHub Bio-Manufacturing Execution System, delivers three principal capabilities: real-time production monitoring, digital batch record management, and embedded quality management. The platform is architected as a cloud-native MES with secure digital workflows purpose-built for regulated environments; its differentiators are domain specialization (workflows designed for cell and gene therapy rather than generalized to all pharma), performance speed (real-time production visibility rather than batch reporting), and integration (quality management embedded directly into the execution layer rather than delivered as a separate bolt-on). The technical stack is not disclosed beyond these functional descriptions.

MyCellHub operates as a B2B enterprise software vendor using a subscription/recurring revenue model based on cloud MES licensing. Go-to-market relies on direct enterprise sales to regulated life sciences manufacturers, with vertical segmentation focused on advanced therapy production and primary pain points centered on paper-based GMP processes, traceability gaps, and 21 CFR Part 11 compliance. The company has been a privately held, VC-backed entity (with reported funding from Gemma Frisius Fund, Meusinvest/Noshaq, LRM, The Faktory Fund, The CoFoundry, and KU Leuven) until its acquisition by Title21 Health Solutions — an ARCHIMED portfolio company — in January 2026, which extends distribution into North America and Australia alongside its Belgian/European base.

Name

MyCellHub

Legal name

MyCellHub

Website

https://mycellhub.com

Company type

Private

Founded year

2019

Operating status

Acquired

Headcount range

11–50 employees

Short description

MyCellHub is a Belgium-based provider of cloud-based Manufacturing Execution System software for regulated life sciences and advanced therapy manufacturers, enabling real-time production monitoring, digital batch records, and embedded quality management for GMP-compliant cell and gene therapy production.

Ownership category

akta.pro rank

Product category

Life Sciences Manufacturing Execution Systems

NAICS

Computer Systems Design and Related Services (54151)

SIC

Services-Computer Programming, Data Processing, Etc. (7370)

akta.pro primary industry

Manufacturing Informatics for Biopharma (MES/EBR/Batch Records for GMP) (HLAGAJAJ)

akta.pro secondary industry

Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES) (HLAAAJAE)

Keywords

• Manufacturing execution system
• Cell therapy software
• GMP compliance platform
• Bioprocess monitoring software
• Life sciences MES

Headquarters

HQ city

Leuven

HQ country

Belgium

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. MES Software Licensing/Subscription: MyCellHub generated revenue through cloud-based MES software licensing and subscription fees for its manufacturing execution system platform designed for regulated life sciences manufacturing. The company was acquired by Title21 Health Solutions in January 2026.

Go-to-market motion1 record

Distribution channels1 record

Core offering

MyCellHub provides a cloud-based Manufacturing Execution System (MES) purpose-built for regulated life sciences and advanced therapy manufacturers (including cell and gene therapy producers). The platform delivers real-time production monitoring, digital batch record management, and embedded quality management, replacing paper-based GMP workflows with secure digital records compliant with 21 CFR Part 11.

Product overview

MyCellHub offers a single unified cloud-based manufacturing execution system for GMP operations in regulated life sciences and advanced therapy manufacturing. The platform provides real-time production monitoring, digital batch record management, and embedded quality management capabilities designed to replace paper-based GMP processes with secure digital workflows compliant with electronic records regulations like 21 CFR Part 11.

Differentiator

Problem solved

Functional benefit

Products and services

• MyCellHub Bio-Manufacturing Execution System

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Title21 Health SolutionscoreStrategic or Co-development Partner · 8 January 2026Title21 Health Solutions, a provider of enterprise quality management systems and cell and gene therapy orchestration platforms and an ARCHIMED portfolio company, acquired MyCellHub in January 2026. The acquisition expands Title21's digital solution portfolio to include MyCellHub's real-time production monitoring, digital batch record management, and embedded quality management capabilities while extending geographic coverage from North America and Australia into Europe.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Direct peers

• Title21 Health Solutions: Acquirer of MyCellHub and provider of enterprise QMS and cell/gene therapy orchestration platforms. Directly comparable as both serve advanced therapy manufacturers with GMP-focused digital software stacks and now share the same product portfolio.
• Werum PAS-X (Körber): Market-leading MES platform purpose-built for pharmaceutical and biopharmaceutical manufacturing, including biologics and cell therapy workflows. Directly competes with MyCellHub for regulated biopharma MES deals and offers similar batch record and GMP compliance capabilities.
• Apprentice.io: Cloud-native manufacturing execution and intelligence platform for life sciences, including cell and gene therapy manufacturers. Directly comparable to MyCellHub as a modern, cloud-based MES targeting similar regulated life sciences customers.

Broad incumbents

• MasterControl: Established provider of quality management and manufacturing execution software for life sciences. Broader portfolio spans QMS, MES, and document management across pharma, medical devices, and biotech, overlapping with MyCellHub's QMS-embedded MES capabilities.
• Veeva Systems: Large life sciences cloud software platform with Vault Manufacturing suite covering batch records, quality, and production execution. Competes for the same regulated life sciences manufacturers as MyCellHub but operates at significantly greater scale.
• Rockwell Automation PharmaSuite: Rockwell's dedicated pharma/biotech MES offering, providing batch execution, electronic batch records, and integration with control systems. Competes with MyCellHub in regulated biopharma manufacturing but as part of a much broader industrial automation portfolio.
• Siemens Opcenter Execution (formerly SIMATIC IT): Siemens's MES solution covering regulated industries including pharmaceuticals and biotech. Overlaps with MyCellHub on production monitoring and batch execution but serves a much wider industrial manufacturing customer base.
• Sparta Systems (Honeywell) TrackWise: Honeywell-owned QMS and manufacturing operations platform widely used in pharma and biotech. Adjacent to MyCellHub on the quality management side, increasingly overlapping on batch record and digital GMP workflows for life sciences customers.

Emerging players

• LabVantage Solutions: Provider of LIMS, ELN, and manufacturing execution software for life sciences labs and production environments. Comparable to MyCellHub in serving regulated life sciences digital workflows, with partial overlap in biopharma manufacturing informatics.
• Tulip Interfaces: No-code manufacturing app platform with growing footprint in life sciences, including pharma and biotech production use cases. Emerging peer to MyCellHub in the cloud MES space, with broader applicability but less depth in cell/gene therapy workflows.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/mycellhub
• LinkedInlinkedin.com/company/mycellhub

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MyCellHub